Clinical and genetic findings in 26 Italian patients with Lafora disease

Silvana Franceschetti, Antonio Gambardella, Laura Canafoglia, Pasquale Striano, Hannes Lohi, Elena Gennaro, Leonarda Ianzano, Pierangelo Veggiotti, Vito Sofia, Roberto Biondi, Salvatore Striano, Cinzia Gellera, Grazia Annesi, Francesca Madia, Donata Civitelli, Francesca E. Rocca, Aldo Quattrone, Giuliano Avanzini, Berge Minassian, Federico Zara

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: EPM2B mutations have been found in a variable proportion of patients with Lafora disease (LD). Genotype-phenotype correlations suggested that EPM2B patients show a slower course of the disease, with delayed age at death, compared with EPM2A patients. We herein report clinical and genetic findings of 26 Italian LD patients. Methods: Disease progression was evaluated by means of a disability scale based on residual motor and cognitive functions and daily living and social abilities, at 4 years from the onset. Mutational analysis was performed by sequencing the coding regions of the EPM2A and EPM2B genes. Results: Age at onset ranged from 8.5 to 18.5 years (mean, 13.7 ± 2.6). The mean duration of follow-up was 7.1 ± 3.9 years. Daily living activities and social interactions were preserved in five of 24 patients. The remaining patients showed moderate to extremely severe limitations of daily living and social abilities. Sixteen (72%) of 22 families showed mutations in the EPM2B gene, and five (22%), in the EPM2A gene. One family showed no mutations. A novel EPM2B mutation also was identified. Conclusions: In our series, EPM2B mutations occurred in 72% of families, thus indicating that EPM2B is the major gene for LD in the Italian population. Moreover, we found that six of 17 EPM2B patients preserved daily living activities and social interactions at 4 years from onset, suggesting a slow disease progression. Additional clinical and functional studies will clarify whether specific mutations may influence the course of the disease in LD patients.

Original languageEnglish (US)
Pages (from-to)640-643
Number of pages4
JournalEpilepsia
Volume47
Issue number3
DOIs
StatePublished - Mar 1 2006

Fingerprint

Lafora Disease
Mutation
Interpersonal Relations
Activities of Daily Living
Genes
Disease Progression
Genetic Association Studies
Age of Onset
Cognition

Keywords

  • Genetics
  • Lafora disease
  • Progressive myoclonic epilepsy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Franceschetti, S., Gambardella, A., Canafoglia, L., Striano, P., Lohi, H., Gennaro, E., ... Zara, F. (2006). Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia, 47(3), 640-643. https://doi.org/10.1111/j.1528-1167.2006.00479.x

Clinical and genetic findings in 26 Italian patients with Lafora disease. / Franceschetti, Silvana; Gambardella, Antonio; Canafoglia, Laura; Striano, Pasquale; Lohi, Hannes; Gennaro, Elena; Ianzano, Leonarda; Veggiotti, Pierangelo; Sofia, Vito; Biondi, Roberto; Striano, Salvatore; Gellera, Cinzia; Annesi, Grazia; Madia, Francesca; Civitelli, Donata; Rocca, Francesca E.; Quattrone, Aldo; Avanzini, Giuliano; Minassian, Berge; Zara, Federico.

In: Epilepsia, Vol. 47, No. 3, 01.03.2006, p. 640-643.

Research output: Contribution to journalArticle

Franceschetti, S, Gambardella, A, Canafoglia, L, Striano, P, Lohi, H, Gennaro, E, Ianzano, L, Veggiotti, P, Sofia, V, Biondi, R, Striano, S, Gellera, C, Annesi, G, Madia, F, Civitelli, D, Rocca, FE, Quattrone, A, Avanzini, G, Minassian, B & Zara, F 2006, 'Clinical and genetic findings in 26 Italian patients with Lafora disease', Epilepsia, vol. 47, no. 3, pp. 640-643. https://doi.org/10.1111/j.1528-1167.2006.00479.x
Franceschetti S, Gambardella A, Canafoglia L, Striano P, Lohi H, Gennaro E et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia. 2006 Mar 1;47(3):640-643. https://doi.org/10.1111/j.1528-1167.2006.00479.x
Franceschetti, Silvana ; Gambardella, Antonio ; Canafoglia, Laura ; Striano, Pasquale ; Lohi, Hannes ; Gennaro, Elena ; Ianzano, Leonarda ; Veggiotti, Pierangelo ; Sofia, Vito ; Biondi, Roberto ; Striano, Salvatore ; Gellera, Cinzia ; Annesi, Grazia ; Madia, Francesca ; Civitelli, Donata ; Rocca, Francesca E. ; Quattrone, Aldo ; Avanzini, Giuliano ; Minassian, Berge ; Zara, Federico. / Clinical and genetic findings in 26 Italian patients with Lafora disease. In: Epilepsia. 2006 ; Vol. 47, No. 3. pp. 640-643.
@article{667d5cbc875d43d8ba58b1521e7c06e3,
title = "Clinical and genetic findings in 26 Italian patients with Lafora disease",
abstract = "Purpose: EPM2B mutations have been found in a variable proportion of patients with Lafora disease (LD). Genotype-phenotype correlations suggested that EPM2B patients show a slower course of the disease, with delayed age at death, compared with EPM2A patients. We herein report clinical and genetic findings of 26 Italian LD patients. Methods: Disease progression was evaluated by means of a disability scale based on residual motor and cognitive functions and daily living and social abilities, at 4 years from the onset. Mutational analysis was performed by sequencing the coding regions of the EPM2A and EPM2B genes. Results: Age at onset ranged from 8.5 to 18.5 years (mean, 13.7 ± 2.6). The mean duration of follow-up was 7.1 ± 3.9 years. Daily living activities and social interactions were preserved in five of 24 patients. The remaining patients showed moderate to extremely severe limitations of daily living and social abilities. Sixteen (72{\%}) of 22 families showed mutations in the EPM2B gene, and five (22{\%}), in the EPM2A gene. One family showed no mutations. A novel EPM2B mutation also was identified. Conclusions: In our series, EPM2B mutations occurred in 72{\%} of families, thus indicating that EPM2B is the major gene for LD in the Italian population. Moreover, we found that six of 17 EPM2B patients preserved daily living activities and social interactions at 4 years from onset, suggesting a slow disease progression. Additional clinical and functional studies will clarify whether specific mutations may influence the course of the disease in LD patients.",
keywords = "Genetics, Lafora disease, Progressive myoclonic epilepsy",
author = "Silvana Franceschetti and Antonio Gambardella and Laura Canafoglia and Pasquale Striano and Hannes Lohi and Elena Gennaro and Leonarda Ianzano and Pierangelo Veggiotti and Vito Sofia and Roberto Biondi and Salvatore Striano and Cinzia Gellera and Grazia Annesi and Francesca Madia and Donata Civitelli and Rocca, {Francesca E.} and Aldo Quattrone and Giuliano Avanzini and Berge Minassian and Federico Zara",
year = "2006",
month = "3",
day = "1",
doi = "10.1111/j.1528-1167.2006.00479.x",
language = "English (US)",
volume = "47",
pages = "640--643",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Clinical and genetic findings in 26 Italian patients with Lafora disease

AU - Franceschetti, Silvana

AU - Gambardella, Antonio

AU - Canafoglia, Laura

AU - Striano, Pasquale

AU - Lohi, Hannes

AU - Gennaro, Elena

AU - Ianzano, Leonarda

AU - Veggiotti, Pierangelo

AU - Sofia, Vito

AU - Biondi, Roberto

AU - Striano, Salvatore

AU - Gellera, Cinzia

AU - Annesi, Grazia

AU - Madia, Francesca

AU - Civitelli, Donata

AU - Rocca, Francesca E.

AU - Quattrone, Aldo

AU - Avanzini, Giuliano

AU - Minassian, Berge

AU - Zara, Federico

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Purpose: EPM2B mutations have been found in a variable proportion of patients with Lafora disease (LD). Genotype-phenotype correlations suggested that EPM2B patients show a slower course of the disease, with delayed age at death, compared with EPM2A patients. We herein report clinical and genetic findings of 26 Italian LD patients. Methods: Disease progression was evaluated by means of a disability scale based on residual motor and cognitive functions and daily living and social abilities, at 4 years from the onset. Mutational analysis was performed by sequencing the coding regions of the EPM2A and EPM2B genes. Results: Age at onset ranged from 8.5 to 18.5 years (mean, 13.7 ± 2.6). The mean duration of follow-up was 7.1 ± 3.9 years. Daily living activities and social interactions were preserved in five of 24 patients. The remaining patients showed moderate to extremely severe limitations of daily living and social abilities. Sixteen (72%) of 22 families showed mutations in the EPM2B gene, and five (22%), in the EPM2A gene. One family showed no mutations. A novel EPM2B mutation also was identified. Conclusions: In our series, EPM2B mutations occurred in 72% of families, thus indicating that EPM2B is the major gene for LD in the Italian population. Moreover, we found that six of 17 EPM2B patients preserved daily living activities and social interactions at 4 years from onset, suggesting a slow disease progression. Additional clinical and functional studies will clarify whether specific mutations may influence the course of the disease in LD patients.

AB - Purpose: EPM2B mutations have been found in a variable proportion of patients with Lafora disease (LD). Genotype-phenotype correlations suggested that EPM2B patients show a slower course of the disease, with delayed age at death, compared with EPM2A patients. We herein report clinical and genetic findings of 26 Italian LD patients. Methods: Disease progression was evaluated by means of a disability scale based on residual motor and cognitive functions and daily living and social abilities, at 4 years from the onset. Mutational analysis was performed by sequencing the coding regions of the EPM2A and EPM2B genes. Results: Age at onset ranged from 8.5 to 18.5 years (mean, 13.7 ± 2.6). The mean duration of follow-up was 7.1 ± 3.9 years. Daily living activities and social interactions were preserved in five of 24 patients. The remaining patients showed moderate to extremely severe limitations of daily living and social abilities. Sixteen (72%) of 22 families showed mutations in the EPM2B gene, and five (22%), in the EPM2A gene. One family showed no mutations. A novel EPM2B mutation also was identified. Conclusions: In our series, EPM2B mutations occurred in 72% of families, thus indicating that EPM2B is the major gene for LD in the Italian population. Moreover, we found that six of 17 EPM2B patients preserved daily living activities and social interactions at 4 years from onset, suggesting a slow disease progression. Additional clinical and functional studies will clarify whether specific mutations may influence the course of the disease in LD patients.

KW - Genetics

KW - Lafora disease

KW - Progressive myoclonic epilepsy

UR - http://www.scopus.com/inward/record.url?scp=33644797241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644797241&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2006.00479.x

DO - 10.1111/j.1528-1167.2006.00479.x

M3 - Article

C2 - 16529633

AN - SCOPUS:33644797241

VL - 47

SP - 640

EP - 643

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 3

ER -